TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Recruiting · NCT06088888 · Registry updated 2025-02-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2025-02-21 | NCT06088888 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
| Shenzhen TargetRx Co., Ltd. | 9 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Seattle | United States | 1 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |